Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, and Chair for the Mayo Clinic, posted on X:
“Shocker for me.
ODAC votes against belantamab risk benefit for myeloma.
I hope that this vote reflects the way the questions were narrowly worded. I still hope the drug still gets FDA approved.”
Noopur Raje, Oncologist at Mass General Cancer Center, shared this post on X, adding:
“Indeed a shocker!
If a drug going against an anti CD38 antibody head to head in a phase III trial shows a survival benefit, a vote against it makes no sense! Toxicity is manageable with appropriate dose reductions and dose intensity!
Bela has made a real difference to patients!”
More posts featuring Vincent Rajkumar.